Small-molecule tyrosine kinase inhibitors or specific antibodies that target RON have been extensively studied in cancer chemotherapy because it is frequently altered in epithelial cancers, such as colon and breast cancers, and receptor splice variants are increasingly implicated in mechanisms underlying oncogenesis, metastasis, and the creation of drug-resistant phenotypes. The gene discussed is MST1R; the disease is cancer.